Tafasitamab plus lenalidomide prolonged OS compared to bendamustine plus rituximab or rituximab plus gemcitabine and oxaliplatin for patients with relapsed/refractory DLBCL in the RE-MIND2 study.
Tafasitamab plus lenalidomide prolonged OS compared to bendamustine plus rituximab or rituximab plus gemcitabine and oxaliplatin for patients with relapsed/refractory DLBCL in the RE-MIND2 study.
Findings from the ZUMA-7 trial suggest axicabtagene ciloleucel is an effective alternative option for the second-line treatment of relapsed or refractory large B-cell lymphoma.
Findings from the ZUMA-7 trial suggest axicabtagene ciloleucel is an effective alternative option for the second-line treatment of relapsed or refractory large B-cell lymphoma.
Results of the phase 3 ZUMA-7 trial confirm axicabtagene ciloleucel had superior EFS to second-line chemoimmunotherapy, standard of care for R/R DLBCL.
Results of the phase 3 ZUMA-7 trial confirm axicabtagene ciloleucel had superior EFS to second-line chemoimmunotherapy, standard of care for R/R DLBCL.
IL-1 receptor inhibitor anakinra demonstrates feasibility in the prevention of CRS and ICANS in patients with LBCL and MCL who receive commercial CD19 CAR T-cells.
IL-1 receptor inhibitor anakinra demonstrates feasibility in the prevention of CRS and ICANS in patients with LBCL and MCL who receive commercial CD19 CAR T-cells.
Clinical study findings suggest that heterogeneity of CAR T-cell infusion products affect the efficacy and toxicity of axi-cel therapy in patients with large B cell lymphoma.
Clinical study findings suggest that heterogeneity of CAR T-cell infusion products affect the efficacy and toxicity of axi-cel therapy in patients with large B cell lymphoma.
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase 3 VERITAC-2 trial, the FDA has approved vepdegestrant for patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
Based on results from the phase 3 VERITAC-2 trial, the FDA has approved vepdegestrant for patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
Based on results from the phase 3 RINGSIDE trial, a New Drug Application for varegacestat has been submitted to the FDA for the treatment of adult patients with desmoid tumors.
Based on results from the phase 3 RINGSIDE trial, a New Drug Application for varegacestat has been submitted to the FDA for the treatment of adult patients with desmoid tumors.
Results from a post hoc analysis of the phase 3 DeFi trial demonstrate that nirogacestat provides consistent clinical benefit across prognostic subgroups of patients with desmoid tumors.
Results from a post hoc analysis of the phase 3 DeFi trial demonstrate that nirogacestat provides consistent clinical benefit across prognostic subgroups of patients with desmoid tumors.
Final results from the phase 3 BRIGHT-2 trial demonstrated that bireociclib plus fulvestrant significantly improves PFS compared with fulvestrant alone in previously treated HR-positive, HER2-negative advanced breast cancer.
Final results from the phase 3 BRIGHT-2 trial demonstrated that bireociclib plus fulvestrant significantly improves PFS compared with fulvestrant alone in previously treated HR-positive, HER2-negative advanced breast cancer.
Results from the phase 3 RECITE trial demonstrated that romiplostim significantly reduced the need for chemotherapy dose modifications in patients with chemotherapy-induced thrombocytopenia.
Results from the phase 3 RECITE trial demonstrated that romiplostim significantly reduced the need for chemotherapy dose modifications in patients with chemotherapy-induced thrombocytopenia.
Results from the phase 3 TACO trial demonstrate that tri-weekly cisplatin provides similar survival with improved safety and quality of life vs weekly dosing in patients with locally advanced cervical cancer.
Results from the phase 3 TACO trial demonstrate that tri-weekly cisplatin provides similar survival with improved safety and quality of life vs weekly dosing in patients with locally advanced cervical cancer.
Based on data from the phase 1/2 CARDINAL study, the FDA has granted breakthrough therapy designation to TERN-701 for previously treated Ph-positive chronic myeloid leukemia.
Based on data from the phase 1/2 CARDINAL study, the FDA has granted breakthrough therapy designation to TERN-701 for previously treated Ph-positive chronic myeloid leukemia.
Results from a phase 1 study demonstrate that HSK42360 shows promising clinical activity with favorable safety in patients with BRAF V600-mutant gliomas.
Results from a phase 1 study demonstrate that HSK42360 shows promising clinical activity with favorable safety in patients with BRAF V600-mutant gliomas.
